Feb 26 2015
Research and Markets has announced the addition of the "Cancer Nanomedicine Market & Pipeline Insight 2015" report to their offering.
During the last decade, there has been significant impact of the emergence of nanotechnology on clinical therapeutics. The pharmaceutical industry has witnessed advances in biocompatible nanoscale drug carriers in the form of liposomes and polymeric nanparticles which have the potential to deliver numerous drugs with more efficiency and safety. The advantages of nanoparticle drug delivery, specifically, at the systemic level, include longer circulation half-lives, improved pharmacokinetics and reduced side effects which are major reasons for its increasing popularity.
In the field of cancer therapy, the nanoparticles could possibly depend heavily on the enhanced permeability and retention effect which is caused by leaky tumor vasculatures for better drug accumulation at the tumor sites. Owing to such benefits, the therapeutic nanoparticles as a form of drug delivery has become a very promising field and has the potential to successfully replace traditional chemotherapy.
The future years are expected to be bright with regards to the development of nanoparticle drug delivery systems for cancer treatment. The identification of nanoparticle materials which are relatively safe and effective in delivering therapeutic agents to the target tumor sites is the need of the hour. The protein polymers from natural sources are considered to be promising materials for constructing the nanocarrier systems.
With the commercial success of albumin-based nanoparticles, there has been significant amount of interest in other proteins also. By rationally designing protein nanoparticles based on their behaviors in the tumor microenvironment and based on cancer cell biology, improved efficacy and safety of cancer therapy can be achieved.
Cancer Nanomedicine Market & Pipeline Insight 2015 Report Highlight
- Nanomedicine for Cancer Therapies
- Cancer Nanoparticles Drug Delivery Systems Classification
- Mechanism of Cancer Nanomedicine Therapy
- Cancer Nanomedicine Clinical Pipeline Overview
- Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase
- Cancer Nanomedicine Clinical Pipeline: 79 Drugs
- Marketed Cancer Nanomedicine: 8 Drugs
Companies Mentioned
- Abraxis BioScience
- Access Pharmaceuticals
- Alnylam Pharmaceuticals
- Arrowhead Research
- BIND Biosciences
- Epeius Biotechnologies
- Nanobiotix
- NanoCarrier
- Nippon Kayaku
- Samyang
- Takeda Pharmaceutical
Source: http://www.researchandmarkets.com/